Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 3/2014

01-06-2014 | Letter to the Editor

Soluble interleukin-2 receptor alpha in preclinical type 1 diabetes

Authors: Stephanie Krause, Andreas Beyerlein, Christiane Winkler, Anita Gavrisan, Christiane Kayser, Ramona Puff, Ezio Bonifacio, Anette-Gabriele Ziegler, Peter Achenbach

Published in: Acta Diabetologica | Issue 3/2014

Login to get access

Excerpt

To the Editor of “Acta Diabetologica”. …
Appendix
Available only for authorised users
Literature
1.
Malek TR, Bayer AL (2004) Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 4:665–674PubMedCrossRef
2.
Maier LM, Anderson DE, Severson CA et al (2009) Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol 182:1541–1547PubMedCentralPubMedCrossRef
3.
Maier LM, Lowe CE, Cooper J et al (2009) IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet 5:e1000322PubMedCentralPubMedCrossRef
4.
Lowe CE, Cooper JD, Brusko T et al (2007) Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet 39:1074–1082PubMedCrossRef
5.
Ziegler AG, Bonifacio B, BABYDIAB-BABYDIET Study Group (2012) Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia 55:1937–1943PubMedCrossRef
Metadata
Title
Soluble interleukin-2 receptor alpha in preclinical type 1 diabetes
Authors
Stephanie Krause
Andreas Beyerlein
Christiane Winkler
Anita Gavrisan
Christiane Kayser
Ramona Puff
Ezio Bonifacio
Anette-Gabriele Ziegler
Peter Achenbach
Publication date
01-06-2014
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 3/2014
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-013-0512-8

Other articles of this Issue 3/2014

Acta Diabetologica 3/2014 Go to the issue

Original Article

Novel enzyme-linked immunosorbent assay for bivalent ZnT8 autoantibodies

Original Article

Parental sleep quality and continuous glucose monitoring system use in children with type 1 diabetes

Original Article

Photodynamic topical antimicrobial therapy for infected foot ulcers in patients with diabetes: a randomized, double-blind, placebo-controlled study—the D.A.N.T.E (Diabetic ulcer Antimicrobial New Topical treatment Evaluation) study

Original Article

Different prevalence of metabolic control and chronic complication rate according to the time of referral to a diabetes care unit in the elderly

Original Article

Changes in weight and BMI following the diagnosis of type 1 diabetes in children and adolescents

Original Article

Assessment of an educational intervention in the management of non-critical inpatient glycemic control
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits